Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
NCT ID: NCT06162507
Last Updated: 2024-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
24 participants
INTERVENTIONAL
2023-12-22
2024-07-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
NCT05579925
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT06116565
Study of CM310 in Adolescent Subjects With Atopic Dermatis
NCT06495229
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
NCT05265923
The Study of CM310 in Patients With Atopic Dermatitis
NCT04893707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CM310 group A
CM310 injection, subcutaneous injection, once every 3 weeks.
CM310
CM310 injection
CM310 group B
CM310 injection, subcutaneous injection, once every 2 weeks.
CM310
CM310 injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM310
CM310 injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntarily sign the informed consent form.
Exclusion Criteria
* With intestinal parasitic infection within the first 6 months of screening.
* With any previous malignant tumors prior to screening.
* With any circumstance that is not suitable to participate in this study.
6 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Children's Hospital Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM310-101010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.